This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Another Run at Health Care Reform: Impact on Healthcare
by Zacks Equity Research
We wait to see how "repealing and replacing" the Obamacare with ACHC proceeds.
ETFs Deserving a Close Watch If Health Care Plans Fail
by Sanghamitra Saha
With Trump's Health Care plans, due for voting today, these ETFs may see considerable movement.
Humana Poised to Grow on Government Business, Strong Capital
by Zacks Equity Research
Humana, Inc. (HUM) stock has long been an investor favorite owing to its strong fundamentals.
Humana's Subsidiaries Receive Rating Action from A.M. Best
by Zacks Equity Research
Humana Inc. (HUM) recently received rating action from A.M. Best. The rating giant has removed from under review, with positive implications, the majority of insurance subsidiaries of the company.
Health Insurers Hit 52-Week Highs: What's Behind the Rise?
by Zacks Equity Research
The rally in the stock is believed to be have occurred from the repeal and replace plan unveiled by the Trump administration.
Will Health Insurers Win Under Obamacare Replacement Plan?
by Zacks Equity Research
While retaining the pre-existing conditions clause might hinder health insurers' business, their ability to charge a penalty on those who fail to maintain coverage is being seen as a positive.
Trump Promises Interstate Coverage Sales, Will It Help Insurance Stocks?
by Ryan McQueeney
Just a day after Republicans unveiled their highly-anticipated plan to repeal and replace Obamacare, President Donald Trump has taken to Twitter to promise that one key provision--eliminating state lines for insurance sales--will come at a later phase in the healthcare rollout.
Teladoc (TDOC) Q4 Loss Lower Than Expected, Guides for '17
by Zacks Equity Research
Teladoc Inc.'s (TDOC) fourth-quarter operating loss of 31 cents per share came in narrower than the Zacks Consensus Estimate of a loss of 35 cents per share.
Humana (HUM) Includes Methodist Healthcare in its Network
by Zacks Equity Research
Humana Inc. (HUM) recently entered into an agreement with Methodist Healthcare to provide better service to its patients.
Select Medical (SEM) Q4 Earnings Miss, Keeps 2017 Guidance
by Zacks Equity Research
Select Medical Holdings Corp. (SEM) reported fourth-quarter 2016 earnings of 12 cents per share, which missed the Zacks Consensus Estimate by a couple of cents.
5 Stocks to Buy for the Post-Obamacare Era
by Swarup Gupta
Insurers, hospitals and healthcare service providers with strong fundamentals would make welcome additions to your portfolio.
Moody's Jumps into Action as Aetna-Humana Deal Fails
by Zacks Equity Research
After the merger deal between Aetna Inc. (AET) and Humana Inc. (HUM) fell through, rating agency Moody's Investors Service jumped into action
Cigna-Anthem Merger Conflict Continues with Countersuit
by Zacks Equity Research
Cigna (CI)-Anthem (ANTM) fight has reached a stage where the focus is on the breakup fee and damages rather than the sealing of the deal.
Health Insurers' Courtship Ends on Valentine's Day
by Zacks Equity Research
More than one and a half years of courtship between Anthem Inc. (ANTM) and Cigna Corp. (CI) as well as Aetna Inc. (AET) and Humana Inc. (HUM) ended yesterday.
Cigna Wants Divorce from Anthem Deal, Sues for Nearly $15 Billion
by Madeleine Johnson
On the heels of Aetna's (AET) and Humana's (HUM) announcement, health insurance competitors Cigna (CI) and Anthem (ANTM) also announced that their merger deal is done-zo on Tuesday.
Aetna, Humana Call Off $34 Billion Courtship in Bad Start to Valentine's Day
by Madeleine Johnson
On Tuesday, health insurance giants Aetna (AET) and Humana (HUM) announced that they have called off their merger agreement after a federal court decision struck down the deal as anticompetitive.
Anthem-Cigna Merger Receives a Blow from Federal Judge
by Zacks Equity Research
As anticipated, the merger between Anthem Inc. (ANTM) and Cigna Corp. (CI) saw the same fate as that of Aetna and Humana which was blocked last month.
Health Insurance Industry Outlook - February 2017
by Zacks Equity Research
The overall uncertain outlook for Obamacare and final regulatory shape of this space continues to be a headwind for the sector as a whole.
Humana (HUM) Beats on Earnings, Misses Revenues in Q4
by Zacks Equity Research
Humana Inc.'s (HUM) fourth-quarter 2016 operating earnings per share of $2.09, which beat the Zacks Consensus Estimate of $2.06 roughly by 1.4%.
Humana's (HUM) Q4 Earnings Beat, Revenues Miss
by Zacks Equity Research
Humana surpassed our earnings estimate in Q4. Our consensus called for EPS of $2.06, and the company reported EPS of $2.09.
Can Humana (HUM) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Humana Inc. (HUM) will release fourth-quarter 2016 results on Feb 8, before the market opens.
Aetna (AET) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
Aetna's (AET) earnings of $1.63 per share, surpassing the Zacks Consensus Estimate of $1.45 and improving 19% year over year.
Aetna (AET) Beats Q4 Earning Estimates, Guides for 2017
by Zacks Equity Research
Aetna (AET) fourth quarter earnings surpassed the estimates.
Aetna (AET) Signs Reinsurance Arrangement with Vitality Re
by Zacks Equity Research
Aetna Inc. (AET) recently signed a four-year reinsurance arrangement with Vitality Re VIII Limited.
4 Reasons Why WellCare Health Stock is a Great Pick Now
by Zacks Equity Research
In spite of the possibility of the reform affecting WellCare Health's business, the company remains an attractive pick for investors.